Tags: Cancer | xgeva | bone | tumor | gctb

New Medication Fights Bone Tumors

Friday, 14 Jun 2013 03:23 PM

 

Share:
A    A   |
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink
Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

The tumor usually affects adults between ages 20 and 40, although it may also develop in adolescents, the FDA said. It typically doesn't spread, although in rare cases it can become cancerous and travel to the lungs.
 
As a non-cancerous tumor, GCTB destroys bone as it becomes larger, causing pain, fractures, and loss of mobility. Xgeva has been approved in cases where the tumor can't be surgically removed, or might lead to a severe outcome such as loss of a limb, the agency said.
 
Xgeva, approved under the FDA's expedited review program, was evaluated for this use in two clinical trials involving a total of 305 adults and adolescents. Common side effects included joint pain, headache, nausea, fatigue, back pain, and extremity pain.
 
Women of childbearing potential should use "highly effective" contraception while taking Xgeva, since the drug can harm a fetus, the FDA warned.
 
The drug was first approved in 2010 to prevent fractures when cancer has spread to the bone. It's marketed by Amgen, based in Thousand Oaks, Calif.

© HealthDay

Share:
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Once-a-Week Diabetes Drug

Tuesday, 15 Apr 2014 12:10 PM

The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 d . . .

Grass Allergy Pill a First for US Sufferers

Wednesday, 02 Apr 2014 07:05 AM

France's Stallergenes has received U.S. regulatory approval to sell the first immunotherapy pill against grass allergies . . .

New Help for Hemophilia Patients

Saturday, 29 Mar 2014 10:07 AM

The Food and Drug Administration has approved the first hemophilia B treatment designed to decrease frequency of injecti . . .

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved